SBIR/STTR Research Award
Screening with D. melanogaster to Discover Inhibitors G12V Mutated kRAS
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- TOSK, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- M5DLPCVDRE95
- Solicitation number
- PA13-234
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): Somatic kRAS mutations, termed oncogenic kRas, are found at a high rate in many cancers. For example, in colon cancer, the rate is 40%. Mutated KRAS allows the EGF system to bypass its natural controls and operate continuously, locked in a pro-growth mode (wild-type kRas, but not oncogenic KRAS, is self- inactivating). Consistent with this mechanism, the presence of mutated KRas predicts lack of response to anti- EGF monoclonal antibody therapeutics such as panitumumab (Vectibix) and cetuximab (Erbitux) in colorectal cancer. The goal of this grant is to discover compounds that specifically inhibit oncogenic kRas without affecting normal kRAS. Such molecules would be expected to restore the anti-cancer efficacy of anti-EGFtherapeutics such as panitumumab and cetuximab when administered to patients with oncogenic kRas. Unfortunately, many previous efforts to target oncogenic KRas have failed, and kRAS has been declared an intractable target by many cancer researchers
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Suppressors of kRAS Activity Discovered Using a Fruit Fly-based In-vivo Screen
- Anchored Antioxidants to Provide Increased Protective Effect
- Targeted gene delivery into whole, adult animals
- Gene delivery into whole, adult, large animals
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
5 SBIR/STTR records share this UEI (2003–2017). Reported award amounts total $2,613,587. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services